Document is current
Any future updates will be listed below
-
Authors
Kaltak, Melita
Blanco-Garavito, Rocio
Molday, Laurie L.
Dhaenens, Claire-Marie
Souied, Eric E.
Platenburg, Gerard
Swildens, Jim
Molday, Robert S.
Cremers, Frans P. M. http://orcid.org/0000-0002-4954-5592
-
Funding
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (813490)
Canadian Institutes of Health Research (PJT 175118)
- License Information
-
More Information
Article History
Received: 5 April 2023
Accepted: 1 August 2023
First Online: 16 August 2023
Declarations
:
: For collecting human samples, written informed consent was obtained before participation. These studies were conducted in accordance with French Law No. 2011-814 of July 7, 2011, Decree 2013-527 of June 20, 2013 and Order of May 27, 2013.
: All authors have read and approved the content of the manuscript and agree to submit for publication in the journal.
: M.K., G.P., and J.S. were employed by ProQR Therapeutics during this project. M.K., and J.S. are inventors on the international patent application (WO 2022/090256) that has been filed by ProQR Therapeutics describing methods and means related to exon 17 skip of <i>ABCA4</i> pre-mRNA by antisense oligonucleotides for treatment of Stargardt disease type 1. The rest of the authors declare that they have no competing interests.
